Your session is about to expire
← Back to Search
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Lupus (POETYK SLE-2 Trial)
Phase 3
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
Summary
This trial is testing a new medication called deucravacitinib to see if it is safe and effective for people with moderate to severe lupus, a disease where the immune system attacks the body. The medication aims to reduce inflammation by targeting specific enzymes in the immune system.
Who is the study for?
This trial is for adults with active moderate to severe Systemic Lupus Erythematosus (SLE) who meet specific criteria, including a certain score on the SLEDAI-2K disease activity index and evidence of joint or skin involvement. Participants may be taking stable doses of steroids, antimalarials, or immunosuppressants but cannot have severe lupus nephritis, other autoimmune diseases except some exceptions, recent major infections, or more than one immunosuppressant.
What is being tested?
The study tests Deucravacitinib's effectiveness and safety against a placebo in treating SLE. Participants will randomly receive either the investigational drug or an inactive substance to compare outcomes between the two groups over time.
What are the potential side effects?
While not specified here, potential side effects could include typical reactions seen with immune-modulating drugs such as increased risk of infection, liver issues, blood cell count changes, nausea, headaches and possible allergic reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2023 Phase 2 trial • 67 Patients • NCT0487799025%
COVID-19
13%
Pneumonia
13%
Nasopharyngitis
8%
Cough
8%
Pyrexia
8%
Mouth ulceration
8%
Upper respiratory tract infection
4%
Urinary tract infection
4%
Small intestinal obstruction
4%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
CROHN'S DISEASE
ULCERATIVE COLITIS
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 1: DeucravacitinibExperimental Treatment1 Intervention
Group II: Arm 2: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~320
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Lupus, such as hydroxychloroquine, glucocorticoids, and immunosuppressive agents like azathioprine, work by modulating the immune system to reduce inflammation and prevent tissue damage. Hydroxychloroquine interferes with antigen presentation and cytokine production, while glucocorticoids suppress overall immune activity.
Immunosuppressive agents inhibit the proliferation of immune cells. Deucravacitinib, a selective TYK2 inhibitor, targets the TYK2 enzyme involved in cytokine signaling pathways critical for immune response.
This specificity can potentially reduce disease activity with fewer side effects. Understanding these mechanisms helps Lupus patients and their doctors choose treatments that effectively manage symptoms while minimizing adverse effects.
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials.New Trials in Lupus and where Are we Going.
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials.New Trials in Lupus and where Are we Going.
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,098,581 Total Patients Enrolled
5 Trials studying Lupus
1,111 Patients Enrolled for Lupus
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My lupus is active, with a score showing moderate to severe symptoms including joint or skin issues.I have lupus with specific symptoms not counting towards my screening score.My lupus was caused by medication, not naturally occurring.I do not have autoimmune diseases like MS or psoriasis, but I may have type 1 diabetes, thyroid issues, Celiac, or Sjögren's.I am taking more than one immunosuppressant.I have severe lupus affecting my kidneys that might need strong medication.I was diagnosed with Lupus more than 24 weeks ago.I have been on a stable dose of my lupus medication for at least 8 weeks.I may or may not be taking a stable dose of oral corticosteroids, not exceeding 30 mg/day.I have tested positive for specific autoimmune markers.I have not had a serious infection or been on strong infection treatments recently.I do not have active or severe neurological lupus symptoms.
Research Study Groups:
This trial has the following groups:- Group 1: Arm 2: Placebo
- Group 2: Arm 1: Deucravacitinib
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.